person · Reporting owner
Verduyn-van Weegen Felice Isabel
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AgomAb Therapeutics NVAGMB · Entity 5259 | Director | March 18, 2026 | March 18, 2026 |
| Evommune, Inc.EVMN · Entity 5539 | Director · 10% owner | February 17, 2026 | February 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AgomAb Therapeutics NV
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.26 · Expires 2036-01-15 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F3: The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026. F1: 33% of the shares underlying this option shall vest on February 9, 2027 with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. F2: The common shares may be represented by American Depositary Shares, each of which currently represents one common share. |
Filing footnotes · ownership attribution and instrument terms
F1: 33% of the shares underlying this option shall vest on February 9, 2027 with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2: The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
F3: The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.
Evommune, Inc.
Report date February 17, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LSP 7 Cooperatief U.A. | 5,288,313 |
Reported balance
After 2026-02-17 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-02-17 · Grant · Acquired 358,680 · Balance 5,288,313 F1: These securities are held by LSP 7 Cooperatief U.A. ("LSP 7"). LSP 7 Management BV ("LSP 7 Management") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are held by LSP 7 Cooperatief U.A. ("LSP 7"). LSP 7 Management BV ("LSP 7 Management") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2026 Filed Feb 19, 2026 02:19 UTC | Evommune, Inc. EVMN · Entity 5539 | GrantCommon Stock | 358,680 | $27.88 | $9,999,998.40 |
DisclosureSEC source: 0002094941-26-000002 · form4-02192026_020236.xml · nonDerivative · entry 1 Verduyn-van Weegen Felice Isabel · CIK 0002094941 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By LSP 7 Cooperatief U.A. Disclosed balance after: 5,288,313 F1 · ownership.nature: These securities are held by LSP 7 Cooperatief U.A. ("LSP 7"). LSP 7 Management BV ("LSP 7 Management") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:24 UTC | Evommune, Inc. EVMN · Entity 5539 | ConversionSeries C Preferred Stock · Derivative | 6,585,011 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002094941-25-000004 · form4-11122025_091104.xml · derivative · entry 5 Verduyn-van Weegen Felice Isabel · CIK 0002094941 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By LSP 7 Cooperatief U.A. Disclosed balance after: 0 Underlying: Common Stock · 773,069 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date. F3 · price: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date. F3 · derivative.exercise_date: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date. F3 · derivative.expiration_date: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date. F4 · ownership.nature: These securities are held by LSP 7 Cooperatief U.A. ("LSP 7"). LSP 7 Management BV ("LSP 7 Management") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:24 UTC | Evommune, Inc. EVMN · Entity 5539 | ConversionSeries B Preferred Stock · Derivative | 5,090,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002094941-25-000004 · form4-11122025_091104.xml · derivative · entry 4 Verduyn-van Weegen Felice Isabel · CIK 0002094941 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By LSP 7 Cooperatief U.A. Disclosed balance after: 0 Underlying: Common Stock · 646,587 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date. F2 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date. F2 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date. F2 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date. F4 · ownership.nature: These securities are held by LSP 7 Cooperatief U.A. ("LSP 7"). LSP 7 Management BV ("LSP 7 Management") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:24 UTC | Evommune, Inc. EVMN · Entity 5539 | ConversionSeries A Preferred Stock · Derivative | 15,493,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002094941-25-000004 · form4-11122025_091104.xml · derivative · entry 3 Verduyn-van Weegen Felice Isabel · CIK 0002094941 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By LSP 7 Cooperatief U.A. Disclosed balance after: 0 Underlying: Common Stock · 1,947,477 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-7.9557 basis and had no expiration date. F1 · price: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-7.9557 basis and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-7.9557 basis and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-7.9557 basis and had no expiration date. F4 · ownership.nature: These securities are held by LSP 7 Cooperatief U.A. ("LSP 7"). LSP 7 Management BV ("LSP 7 Management") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:24 UTC | Evommune, Inc. EVMN · Entity 5539 | PurchaseCommon Stock | 1,562,500 | $16.00 | $25,000,000.00 |
DisclosureSEC source: 0002094941-25-000004 · form4-11122025_091104.xml · nonDerivative · entry 2 Verduyn-van Weegen Felice Isabel · CIK 0002094941 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By LSP 7 Cooperatief U.A. Disclosed balance after: 4,929,633 F4 · ownership.nature: These securities are held by LSP 7 Cooperatief U.A. ("LSP 7"). LSP 7 Management BV ("LSP 7 Management") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:24 UTC | Evommune, Inc. EVMN · Entity 5539 | ConversionCommon Stock | 3,367,133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002094941-25-000004 · form4-11122025_091104.xml · nonDerivative · entry 1 Verduyn-van Weegen Felice Isabel · CIK 0002094941 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By LSP 7 Cooperatief U.A. Disclosed balance after: 3,367,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") for no additional consideration on a 1-for-7.9557 basis and had no expiration date. F2 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date. F3 · price: Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date. F4 · ownership.nature: These securities are held by LSP 7 Cooperatief U.A. ("LSP 7"). LSP 7 Management BV ("LSP 7 Management") may be deemed to beneficially own these securities. As managing directors of LSP 7 Management, each of Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may also be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest, if any, therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.